Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 7;14(15):5597.
doi: 10.3390/jcm14155597.

GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus

Javier Crespo  1 , Juan Carlos Rodríguez-Duque  2 , Paula Iruzubieta  2 , Eliana C Morel Cerda  3 , Jose Antonio Velarde-Ruiz Velasco  3
Affiliations
Review

GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus

Javier Crespo et al. J Clin Med. .

Abstract

Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes mellitus and obesity. However, their sustained effect on delaying gastric emptying raises new challenges in gastrointestinal endoscopy performed under sedation. This narrative review aims to summarize current evidence on the impact of GLP-1 RAs on gastric motility and to propose clinical strategies to mitigate associated procedural risks. Methods: A narrative review was conducted integrating findings from scintigraphy, capsule endoscopy, gastric ultrasound, and existing clinical guidelines. Emphasis was placed on studies reporting residual gastric content (RGC), anesthetic safety outcomes, and procedural feasibility in patients undergoing endoscopy while treated with GLP-1 RAs. Results: GLP-1 RAs significantly increase the prevalence of clinically relevant RGC, despite prolonged fasting, with potential implications for airway protection and sedation safety. Although the risk of pulmonary aspiration remains low (≤0.15%), procedural delays, modifications, or cancellations can occur in up to 30% of cases without adapted protocols. Several professional societies (AGA, ASGE, AASLD) advocate for individualized management based on procedure type, symptomatology, treatment phase, and point-of-care gastric ultrasound (POCUS), in contrast to the systematic discontinuation recommended by the ASA. Conclusions: Effective management requires personalized fasting protocols, risk-based stratification, tailored anesthetic approaches, and interprofessional coordination. We propose a clinical decision algorithm and highlight the need for training in gastrointestinal pharmacology, POCUS, and airway management for endoscopists. Future priorities include prospective validation of clinical algorithms, safety outcome studies, and the development of intersocietal consensus guidelines.

Keywords: GLP-1 receptor agonists; endoscopy; risk.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Suggested integrated Clinical Decision Algorithm (Sequential and Operational Version). GLP-1RA: glucagon-like peptide-1 receptor agonist; BMI: body mass index; POCUS: point-of-care gastric ultrasound.
Figure 2
Figure 2
Suggested Protocol for Managing GLP-1 RA Treatment Around Endoscopic Procedures. GLP-1 RA: glucagon-like peptide-1 receptor agonist.
See this image and copyright information in PMC

References

    1. Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N. Engl. J. Med. 2021;384:989–1002. doi: 10.1056/NEJMoa2032183. - DOI - PubMed
    1. Madsbad S., Kielgast U., Asmar M., Deacon C.F., Torekov S.S., Holst J.J. An overview of once-weekly glucagon-like peptide-1 receptor agonists—Available efficacy and safety data and perspectives for the future. Diabetes Obes. Metab. 2011;13:394–407. doi: 10.1111/j.1463-1326.2011.01357.x. - DOI - PubMed
    1. Meier J.J., Nauck M.A. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab. Res. Rev. 2005;21:91–117. doi: 10.1002/dmrr.538. - DOI - PubMed
    1. Marathe C.S., Rayner C.K., Jones K.L., Horowitz M. Glucagon-like peptides 1 and 2 in health and disease: A review. Peptides. 2013;44:75–86. doi: 10.1016/j.peptides.2013.01.014. - DOI - PubMed
    1. Hiramoto B., McCarty T.R., Lodhia N.A., Jenkins A., Elnaiem A., Muftah M., Flanagan R., Chan W.W. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management. Am. J. Gastroenterol. 2024;119:1126–1140. doi: 10.14309/ajg.0000000000002820. - DOI - PMC - PubMed

LinkOut - more resources